Biocon Q1 Revenue Hits Rs 39.4 Billion, Up 15 Per Cent
ECONOMY & POLICY

Biocon Q1 Revenue Hits Rs 39.4 Billion, Up 15 Per Cent

Biocon Limited, a global innovation-driven biopharmaceutical company, reported a consolidated operating revenue of Rs 39.4 billion for the quarter ended 30 June 2025 (Q1 FY26), marking a 15 per cent increase year-on-year. On a like-for-like basis, excluding the divestment gain from the previous year, EBITDA rose 19 per cent to Rs 8.3 billion, while Profit Before Tax (before exceptional items) increased 72 per cent to Rs 970 million.
Core EBITDA stood at Rs 10 billion with a 25 per cent margin, supported by strong performances across business segments.

Segment Highlights:
  • Biosimilars: Revenue reached Rs 24.6 billion, up 18 per cent YoY. EBITDA rose 36 per cent to Rs 6.45 billion, with a margin of 26 per cent.
  • Generics: Revenue stood at Rs 6.97 billion, up 6 per cent YoY, driven by new product launches in the US and Europe.
  • CRDMO (Syngene): Revenue rose 11 per cent YoY to Rs 8.75 billion. EBITDA reached Rs 2.24 billion.
Biocon’s net R&D investment was Rs 2.05 billion, amounting to 7 per cent of revenue (excluding Syngene).

Leadership Commentary:
Kiran Mazumdar-Shaw, Chairperson, stated that Biocon entered FY26 with strong momentum, particularly in biosimilars and CRDMO, adding that recent US FDA approvals and launches in Canada and Europe strengthen Biocon’s global footprint.
Siddharth Mittal, CEO of Biocon Limited, noted that generics growth was driven by the successful launch of products such as Liraglutide in the EU and Dasatinib in the US.
Shreehas Tambe, CEO of Biocon Biologics, confirmed a strong 18 per cent growth in biosimilars revenue, highlighting approvals for biosimilars including Kirsty™ (Insulin Aspart) and Yesafili™ (Aflibercept).
Peter Bains, CEO of Syngene, attributed the 11 per cent rise in CRDMO revenue to successful transitions of pilot projects to long-term contracts.
Corporate Developments:
Biocon raised Rs 45 billion via a Qualified Institutional Placement (QIP) in June 2025 to increase its stake in Biocon Biologics and provide exits for equity investors.
Sustainability Achievements:
Biocon received a gold rating from EcoVadis, placing it in the top 5 per cent globally for sustainability. Syngene was ranked India’s most sustainable pharma/biotech firm by TIME and Statista.
Regulatory Milestones:
Biocon’s API sites in Visakhapatnam and Bengaluru passed Brazil’s ANVISA audits with zero observations. Its Bengaluru facility was also inspected by the Malta Medicines Authority.
Outlook:
With expanded manufacturing capacity and continued innovation, Biocon is confident of long-term growth across biosimilars, generics, and CRDMO, further supporting its mission of affordable access to complex therapies worldwide. 

Biocon Limited, a global innovation-driven biopharmaceutical company, reported a consolidated operating revenue of Rs 39.4 billion for the quarter ended 30 June 2025 (Q1 FY26), marking a 15 per cent increase year-on-year. On a like-for-like basis, excluding the divestment gain from the previous year, EBITDA rose 19 per cent to Rs 8.3 billion, while Profit Before Tax (before exceptional items) increased 72 per cent to Rs 970 million.Core EBITDA stood at Rs 10 billion with a 25 per cent margin, supported by strong performances across business segments.Segment Highlights:Biosimilars: Revenue reached Rs 24.6 billion, up 18 per cent YoY. EBITDA rose 36 per cent to Rs 6.45 billion, with a margin of 26 per cent.Generics: Revenue stood at Rs 6.97 billion, up 6 per cent YoY, driven by new product launches in the US and Europe.CRDMO (Syngene): Revenue rose 11 per cent YoY to Rs 8.75 billion. EBITDA reached Rs 2.24 billion.Biocon’s net R&D investment was Rs 2.05 billion, amounting to 7 per cent of revenue (excluding Syngene).Leadership Commentary:Kiran Mazumdar-Shaw, Chairperson, stated that Biocon entered FY26 with strong momentum, particularly in biosimilars and CRDMO, adding that recent US FDA approvals and launches in Canada and Europe strengthen Biocon’s global footprint.Siddharth Mittal, CEO of Biocon Limited, noted that generics growth was driven by the successful launch of products such as Liraglutide in the EU and Dasatinib in the US.Shreehas Tambe, CEO of Biocon Biologics, confirmed a strong 18 per cent growth in biosimilars revenue, highlighting approvals for biosimilars including Kirsty™ (Insulin Aspart) and Yesafili™ (Aflibercept).Peter Bains, CEO of Syngene, attributed the 11 per cent rise in CRDMO revenue to successful transitions of pilot projects to long-term contracts.Corporate Developments:Biocon raised Rs 45 billion via a Qualified Institutional Placement (QIP) in June 2025 to increase its stake in Biocon Biologics and provide exits for equity investors.Sustainability Achievements:Biocon received a gold rating from EcoVadis, placing it in the top 5 per cent globally for sustainability. Syngene was ranked India’s most sustainable pharma/biotech firm by TIME and Statista.Regulatory Milestones:Biocon’s API sites in Visakhapatnam and Bengaluru passed Brazil’s ANVISA audits with zero observations. Its Bengaluru facility was also inspected by the Malta Medicines Authority.Outlook:With expanded manufacturing capacity and continued innovation, Biocon is confident of long-term growth across biosimilars, generics, and CRDMO, further supporting its mission of affordable access to complex therapies worldwide. 

Next Story
Real Estate

Bennet & Bernard Unveil Dutch-Inspired ‘Casa El Toledo’ in Goa

Bennet & Bernard Group, Goa’s leading luxury real estate developer, has launched its newest project, Casa El Toledo, in Assagao. The enclave features 18 ultra-luxury 4 BHK Dutch-style villas blending European charm with tropical elegance. Each villa includes a private pool, double-height ceilings, open courtyards, alfresco dining areas, and English-inspired landscaping. The interiors are curated by noted Dutch designer Kelly Marie.   Reflecting the grandeur of the Dutch Golden Age, Casa El Toledo harmonises heritage aesthetics with modern sensibilities. Expansive interiors flow..

Next Story
Equipment

Godrej Delivers Heaviest Ecolaire Surface Condenser to US Project

Godrej Enterprises Group’s Process Equipment business has manufactured and delivered its heaviest Ecolaire® Surface Condenser to date, weighing nearly 450 metric tonnes, for a power-generation project in the United States. The project, powered by natural gas and partly designed for hydrogen compatibility, marks another step in advancing clean energy systems. Produced at the company’s GreenCo-certified Dahej facility in Gujarat, the equipment demonstrates India’s growing engineering capabilities and reinforces Godrej’s ‘Make in India for the World’ vision.  Hussain S..

Next Story
Infrastructure Energy

India, Brazil Discuss Energy Ties And Oil Investments

Union Minister for Petroleum and Natural Gas Hardeep Singh Puri held discussions with Celso Luis Nunes Amorim, Special Advisor to the President of Brazil, and senior Brazilian officials to strengthen bilateral cooperation in the oil, gas, and energy transition sectors. The talks took place during a dinner hosted by Kenneth H da Nobrega, Ambassador of Brazil to India, at his residence in New Delhi.Mr Puri said the meeting focused on Indian investments in Brazil’s oil and gas sector, as well as expanding collaboration in energy transition and biofuels. “The enriching conversation revolved ar..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?